Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Opinion in Cardiology|October 27, 2004
Biomarkers in pulmonary embolismMaaike Söhne, Marije Ten Wolde, Harry R Büller
Thrombosis and Haemostasis|August 23, 2005
Diagnostic strategy using a modified clinical decision rule and D-dimer test to rule out pulmonary embolism in elderly in- and outpatientsMaaike Söhne, Pieter W Kamphuisen, Patricia J W B van Mierlo, et al.
Archives of Internal Medicine|August 11, 2004
Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolismMarije ten Wolde, Maaike Söhne, Elske Quak, et al.
Thrombosis and Haemostasis|February 23, 2010
Application of a decision rule and a D-dimer assay in the diagnosis of pulmonary embolismNadine S Gibson, Renee A Douma, Alessandro Squizzato, et al.
British Journal of Clinical Pharmacology|February 25, 2020
Quality of clinical direct oral anticoagulant prescribing and identification of risk factors for inappropriate prescriptionsZhu Xian Zhang, Ewoudt M W van de Garde, Maaike Söhne, et al.
Thrombosis and Haemostasis|July 29, 2010
Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorationsRenée A Douma, Geerte L van Sluis, Pieter W Kamphuisen, et al.
BMJ (Clinical Research Ed.)|April 1, 2010
Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohortsRenée A Douma, Grégoire le Gal, Maaike Söhne, et al.
Chest|February 14, 2007
The natural course of hemodynamically stable pulmonary embolism: Clinical outcome and risk factors in a large prospective cohort studyMathilde Nijkeuter, Maaike Söhne, Lidwine W Tick, et al.
Thrombosis and Haemostasis|June 6, 2007
Clinically suspected acute recurrent pulmonary embolism: a diagnostic challengeMathilde Nijkeuter, Hanneke Kwakkel-van Erp, Maaike Söhne, et al.
Blood Advances|September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSGerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Pageof 2